Clinical and economic outcomes of pharmacological stress tests in patients with a history of COVID-19.

Hicham Skali David R WalkerJeanette JiangGiridharan GurumoorthyKalatu DaviesTomomi Kimura

Published in: Clinical cardiology (2023)

COVID-19 history was associated with slightly higher reversal agent use, all-cause costs, and office visits after pharmacologic MPI; however, the differences were not clinically meaningful. Concerns for use of stress agents in patients with prior COVID-19 do not appear to be warranted.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
stress induced
type diabetes
metabolic syndrome
skeletal muscle
insulin resistance
life cycle